Eli Lilly Acquires Kelonia Therapeutics for $3.2 Billion in Major Biotech Takeover Deal

Eli Lilly has agreed to acquire Kelonia Therapeutics, a clinical-stage biotechnology company developing in vivo CAR-T cell therapies, for $3.25 billion upfront with potential milestone payments that could bring the total value to $7 billion.

The acquisition represents a significant investment in next-generation cancer immunotherapy, specifically targeting multiple myeloma through Kelonia’s lead program, KLN-1010, an investigational one-time intravenous gene therapy designed to generate anti-BCMA CAR-T cells inside the patient’s body.

Unlike conventional autologous CAR-T therapies, which require harvesting a patient’s T-cells, engineering them in a laboratory, and reintroducing them after chemotherapy preconditioning, Kelonia’s in vivo approach uses engineered lentiviral-based particles to reprogram T-cells directly within the body, eliminating the need for complex manufacturing and lymphodepletion regimens.

The technology, known as iGPS (in vivo gene placement system), aims to simplify delivery and broaden access to CAR-T treatments by enabling the patient’s own body to generate therapeutic cells without ex vivo manufacturing.

Financial Terms and Milestone Structure

Under the agreement, Eli Lilly will pay $3.25 billion in upfront cash to Kelonia Therapeutics shareholders, with additional payments contingent upon the achievement of specific clinical, regulatory, and commercial milestones that could increase the total deal value to $7.0 billion.

The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals and customary closing conditions.

Kelonia’s Technology and Pipeline

Kelonia Therapeutics is developing a proprietary in vivo gene placement system called iGPS, which uses engineered lentiviral-based particles designed to enter T-cells inside a patient’s body to generate CAR-T therapies without the manufacturing complexity associated with conventional autologous CAR-T treatments.

Clinical Progress and Market Context

Early clinical results from Kelonia’s Phase 1 trial of KLN-1010 were presented in the plenary session of the 2025 ASH Annual Meeting, demonstrating promising activity in patients with relapsed or refractory multiple myeloma.

Strategic Significance for Eli Lilly

The acquisition marks Eli Lilly’s second in vivo CAR-T company purchase of the year, following its earlier investment in the space, and reflects a strategic shift beyond its recent dominance in obesity therapeutics into next-generation cancer immunotherapy platforms.

Background on Kelonia Therapeutics

Kelonia Therapeutics, a privately held company, had previously subsisted on approximately $60 million in funding over the last five years and faced financial challenges, coming within a week of running out of cash on multiple occasions prior to the acquisition.

Statnews Coverage and VC Perspective

The acquisition was discussed in detail on STAT’s biotech podcast “The Readout Loud,” where Bryan Roberts, a partner at Venrock — the venture capital firm that incubated Kelonia — shared insights into how the struggling startup secured such a significant deal with Eli Lilly.